

Elevidys[™] (delandistrogene moxeparvovec-rokl) Medication **Precertification Request** Page 1 of 1

Aetna Precertification Notification Phone: 1-866-752-7021 (TTY: 711) FAX: 1-888-267-3277

For Medicare Advantage Part B: Please Use Medicare Request Form

(All fields must be completed and legible for precertification review.)	

Please indicate: Start of treatment: Start date ____ Continuation of therapy, Date of last treatment

Phone:

Precertification Requested By:			Phone	e:	Fax:			
A. PATIENT INFORMATION								
First Name:		Last Name:			DOB:			
Address:		City:			State:	ZIP:		
Home Phone:	Work Phone:		Cell Phone:		Email:	_		
Patient Current Weight: lbs or kgs Patie		nt Height: inches	or <u>cms</u>	Allergies:				
B. INSURANCE INFORMATION								
Aetna Member ID #:		Does patient have othe	•					
Group #:		If yes, provide ID#: Carrier Name:						
Insured:		Insured:						
Medicare: Yes No If yes, provi	de ID #:	Med	licaid: 🗌 Yes	□ No If yes, prov	/ide ID #:			
C. PRESCRIBER INFORMATION		1 4 N I		(Cheeli O				
First Name:		Last Name:		(Uneck U] D.O. N.P. P.A.		
Address:		City:			State:	ZIP:		
Phone: Fax:		St Lic #:	NPI #:	DEA #:	1	UPIN:		
Provider Email:		Office Contact Name:			Phone:			
Specialty (Check one): 🗌 Neurologis	t 🗌 Other:							
D. DISPENSING PROVIDER/ADMINIS	TRATION INFO	RMATION						
Place of Administration:				Provider/Pharmac	-			
-	cian's Office		-		Retail Pharn	nacy		
Outpatient Infusion Center Pl	none:		_ D Specialty	Pharmacy	Other			
Center Name: Home Infusion Center Pl			Name:					
Agency Name:			Address:					
Administration code(s) (CPT):								
Address:			TIN:		PIN:			
E. PRODUCT INFORMATION								
Request is for: Elevidys (delandistro	ogene moxeparv	vovec-rokl) Dose:		Frequency:				
F. DIAGNOSIS INFORMATION - Please	se indicate prima	ry ICD code and specify	y any other wher	e applicable.				
Primary ICD Code:		Secondary ICD Code	e:	Other	ICD Code:			
G. CLINICAL INFORMATION - Requir	ed clinical inform	ation must be complete	d in its <u>entirety</u> f	or all precertificatio	n requests.			
For ALL Requests (clinical documentat	ion required):							
 Yes No Does the patient have a diagnosis of Duchenne muscular dystrophy (DMD)? Yes No Will the requested medication be prescribed by or in consultation with a physician who specializes in the treatment of Duchenne muscular dystrophy (DMD)? 								
Yes No Does the patient have a c	definitive diagnosis			confirmed via gene	tic testing?			
└────────────────────────────────────								
			-	e.q., casimersen, ete	eplirsen, golodirs	en, viltolarsen)?		
 Yes No Will the requested medication be used in combination with exon-skipping therapies (e.g., casimersen, eteplirsen, golodirsen, viltolarsen)? Yes No Is the patient ambulatory (e.g., able to walk with or without assistance, not wheelchair dependent)? 								
 ☐ Yes ☐ No Is patient's anti-adeno-associated virus rh74 (AAVrh74) total binding antibody titers less than 1:400? ☐ Yes ☐ No Has the patient previously received the requested medication? 								
☐ Yes ☐ No Has the patient previous			rokl) be provided	at an Aetna gene th	erapy designate	d center?		
Please provide the name of the gene ther				-				
H. ACKNOWLEDGEMENT								
Request Completed By (Signature	Required):				Date:			
Any person who knowingly files a re- deceive any insurance company by commits a fraudulent insurance act, v	providing mate	erially false information	n or conceals r	material information	on for the purp			

The plan may request additional information or clarification, if needed, to evaluate requests. 2076 (6-24)